Literature DB >> 11442493

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

F M Abu-Duhier1, A C Goodeve, G A Wilson, R S Care, I R Peake, J T Reilly.   

Abstract

Genomic DNA from 97 cases of adult de novo acute myeloid leukaemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations. Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change. In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541 + 57 A-->G, the patient PCR products were digested with EcoRV and NlaIII respectively. Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1). Alterations affecting Asp835 were not found in 80 normal control DNA samples. In contrast, the nucleotide 2541 + 57 A-->G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele. This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homology with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442493     DOI: 10.1046/j.1365-2141.2001.02850.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  99 in total

1.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

Review 2.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 3.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 4.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 5.  Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.

Authors:  Rahul Pawar; Omar Preet Singh Bali; Bharat Kumar Malhotra; Gurpreet Lamba
Journal:  Stem Cell Investig       Date:  2014-03-20

Review 6.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

7.  Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Authors:  Pradeep S Chauhan; Bharat Bhushan; Ashwani K Mishra; Laishram C Singh; Sumita Saluja; Saurabh Verma; Dipendra K Gupta; Vishakha Mittal; Sumita Chaudhry; Sujala Kapur
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

8.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Authors:  Magda Bahcall; Taebo Sim; Cloud P Paweletz; Jyoti D Patel; Ryan S Alden; Yanan Kuang; Adrian G Sacher; Nam Doo Kim; Christine A Lydon; Mark M Awad; Michael T Jaklitsch; Lynette M Sholl; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.